

US\$1.77bn
Market Cap.

44.33%
Free Float

US\$6.61mn
Avg. Daily Value traded

Middle East Healthcare Co.

Q4 miss, pressure in Riyadh and Jeddah

The 4Q24 results reiterated our thesis that rising competition in its home market, Jeddah, as well as in Riyadh, would weigh on its earnings. The decline in Riyadh revenues were much larger than expected at 19% y-o-y. Even in 3Q24, revenues in Riyadh were down 9% y-o-y. At the same time, Jeddah revenues were also down 3% y-o-y (impact calculated based on regional mix shared by the company). For the overall group in 4Q24, insurance and cash revenues were down on a y-o-y basis, while MoH revenues spiked. In our view, insurance and cash patients are vulnerable in terms of shifting to other hospital operators. Thus, the Q4 numbers imply that competition in Riyadh and Jeddah, could be the reason for weaker revenues in 4Q24. On the positive side, the company continues to grow its revenues in Dammam (+19% y-o-y) and Makkah (+53% y-o-y). Further, the company has now received approval to increase the capacity of its Dammam hospital to 300 licensed beds from 150 beds before. Also, both the Dammam and Makkah hospitals have received HIMSS accreditation, thus pricing could improve in 2025. Overall, the company guides for 2025 revenue growth in teens and improvement in EBITDA. However, we prefer to be conservative given that Al Habib will open its second hospital in Jeddah and in Riyadh the Sahafa hospital will witness further ramp-up. We estimate about 10% revenue growth in 2025 and broadly similar EBITDA margins. However, given that 2024 net income had impact of one-offs, our 2025 net income is largely flat y-o-y. In the backdrop of modest growth assumptions in 2025 and the increasing risk of market share loss in Riyadh and Jeddah, we now value the company at a lower multiple of 25x. Thus, we reduce our target price to SAR 76/share from SAR 82/share. We remain neutral on the stock.

Q4 2024 Earnings: Revenues of SAR 749mn (+4% y-o-y and +2% q-o-q) was a miss versus ours estimates. The revenue growth was impacted by lower revenues in Riyadh and Jeddah. The impact was curtailed by solid performance of Makkah and Dammam hospitals. Both gross profits and operating profits were a miss. However, reported net income benefited from one-off gain of SAR 45 mn. Adjusted for that, net income was a modest 3% miss.

Figure 1 Summary of 4Q24 Earnings							
(SAR mn)	Q4 2024	Q4 2023	Q3 2024	ARC Est.	y-o-y	q-o-q	vs ARC
Revenue	749	720	732	769	4%	2%	-3%
Gross Profit	282	294	293	308	-4%	-4%	-8%
G. margin	37.7%	40.8%	40.0%	40.0%			
Op. profit	102	69	116	114	48%	-12%	-10%
Op. margin	13.6%	9.5%	15.8%	14.8%			
Net profit	107	(127)	62		NA	74%	
Net margin	14.3%	-17.6%	8.4%				
One-off gain	45						
ZATCA Provisions		(171)					
Adjusted Net profit*	62	44	62	64	39%	0%	-4%
Adjusted Net margin	8.2%	6.2%	8.4%	8.3%			

Source: Company Data, Al Rajhi Capital estimates

Neutral

Price Target (SAR): 76.0

Current : 72.3

Upside/Downside: 5.1% above current

Valuation Multiples	24A	25E	26E
P/E (x)	23.6	23.7	21.4
P/B (x)	4.1	3.5	3.0

Major Shareholders % Ownership

Bait Al-Batterjee Medical Co.	54.69
-------------------------------	-------

Price Performance	1M	3M	YTD
Absolute	-14.3%	-0.8%	5.2%
Relative to TASI	-9.3%	0.2%	7.1%

Earnings

(SARmn)	2024	2025E	2026E	2027E
Revenue	2,883	3,161	3,537	3,833
Revenue growth	8.7%	9.6%	11.9%	8.4%
Gross profit	1,114	1,211	1,327	1,410
Gross margin	38.6%	38.3%	37.5%	36.8%
Operating profit	441	481	519	544
Op. margins	15.3%	15.2%	14.7%	14.2%
Net profit	282	280	312	357
Net margin	9.8%	8.9%	8.8%	9.3%
EPS	3.06	3.05	3.39	3.88
P/E	23.6x	23.7x	21.4x	18.6x

Source: Company data, Al Rajhi Capital


Valuations: As we trim our revenue estimates for 2025 as well as lower our target multiple, we reduce our target price. We value the company on a P/E methodology and apply a multiple of 25x, lower than before as well as other comparable names such as Dallah (target multiple 30x). The reason for the discount is the rising competitive risk in its home market, Jeddah, and relatively weaker balance sheet. Our target price of SAR 76/share is derived through 25x P/E multiple applied on 2025E EPS of SAR 3.05/share. At our new target price, the upside is about 5%, implying neutral recommendation on the stock.

Figure 2 Valuations

Valuation	Values
Forward P/E	25.0x
2025E EPS	3.05
Fair value per share (SAR)	76.0
CMP	72.3
Upside/Downside	5.1%


Source: Al Rajhi Capital estimates

Figure 3 Revenue by region wise over the last 8 quarters



Source: Company Data, Al Rajhi Capital

Figure 4 Payor mix trend over the last 8 quarters



Source: Company Data, Al Rajhi Capital

IMPORTANT DISCLOSURES FOR U.S. PERSONS

This research report was prepared by Al Rajhi Capital (Al Rajhi), a company authorized to engage in securities activities in Saudi Arabia. Al Rajhi is not a registered broker-dealer in the United States and, therefore, is not subject to U.S. rules regarding the preparation of research reports and the independence of research analysts. This research report is provided for distribution to "major U.S. institutional investors" in reliance on the exemption from registration provided by Rule 15a-6 of the U.S. Securities Exchange Act of 1934, as amended (the "Exchange Act").

Under no circumstances should any recipient of this research report effect any transaction to buy or sell securities or related financial instruments through Al Rajhi.

The analyst whose name appears in this research report is not registered or qualified as a research analyst with the Financial Industry Regulatory Authority ("FINRA") and, therefore, may not be subject to applicable restrictions under FINRA Rules on communications with a subject company, public appearances and trading securities held by a research analyst account.

Additional Disclosures

This research report is for distribution only under such circumstances as may be permitted by applicable law. This research report has no regard to the specific investment objectives, financial situation or particular needs of any specific recipient, even if sent only to a single recipient. This research report is not guaranteed to be a complete statement or summary of any securities, markets, reports or developments referred to in this research report.

Neither Al Rajhi nor any of its directors, officers, employees or agents shall have any liability, however arising, for any error, inaccuracy or incompleteness of fact or opinion in this research report or lack of care in this research report's preparation or publication, or any losses or damages which may arise from the use of this research report.

Al Rajhi may rely on information barriers, such as "Chinese Walls" to control the flow of information within the areas, units, divisions, groups, or affiliates of Al Rajhi.

Investing in any non-U.S. securities or related financial instruments (including ADRs) discussed in this research report may present certain risks. The securities of non-U.S. issuers may not be registered with, or be subject to the regulations of, the U.S. Securities and Exchange Commission. Information on such non-U.S. securities or related financial instruments may be limited. Foreign companies may not be subject to audit and reporting standards and regulatory requirements comparable to those in effect within the United States.


The value of any investment or income from any securities or related financial instruments discussed in this research report denominated in a currency other than U.S. dollars is subject to exchange rate fluctuations that may have a positive or adverse effect on the value of or income from such securities or related financial instruments.

Past performance is not necessarily a guide to future performance and no representation or warranty, express or implied, is made by Al Rajhi with respect to future performance. Income from investments may fluctuate. The price or value of the investments to which this research report relates, either directly or indirectly, may fall or rise against the interest of investors. Any recommendation or opinion contained in this research report may become outdated as a consequence of changes in the environment in which the issuer of the securities under analysis operates, in addition to changes in the estimates and forecasts, assumptions and valuation methodology used herein.

No part of the content of this research report may be copied, forwarded or duplicated in any form or by any means without the prior consent of Al Rajhi and Al Rajhi accepts no liability whatsoever for the actions of third parties in this respect. This research document has been prepared by Al Rajhi Capital Company ("Al Rajhi Capital") of Riyadh, Saudi Arabia. It has been prepared for the general use of Al Rajhi Capital's clients and may not be redistributed, retransmitted or disclosed, in whole or in part, or in any form or manner, without the express written consent of Al Rajhi Capital. Receipt and review of this research document constitute your agreement not to redistribute, retransmit, or disclose to others the contents, opinions, conclusion, or information contained in this document prior to public disclosure of such information by Al Rajhi Capital. The information contained was obtained from various public sources believed to be reliable but we do not guarantee its accuracy. Al Rajhi Capital makes no representations or warranties (express or implied) regarding the data and information provided and Al Rajhi Capital does not represent that the information content of this document is complete, or free from any error, not misleading, or fit for any particular purpose. This research document provides general information only. Neither the information nor any opinion expressed constitutes an offer or an invitation to make an offer, to buy or sell any securities or other investment products related to such securities or investments. It is not intended to provide personal investment advice and it does not take into account the specific investment objectives, financial situation and the particular needs of any specific person who may receive this document.

Investors should seek financial, legal or tax advice regarding the appropriateness of investing in any securities, other investment or investment strategies discussed or recommended in this document and should understand that statements regarding future prospects may not be realized. Investors should note that income from such securities or other investments, if any, may fluctuate and that the price or value of such securities and investments may rise or fall. Fluctuations in exchange rates could have adverse effects on the value of or price of, or income derived from, certain investments. Accordingly, investors may receive back less than originally invested. Al Rajhi Capital or its officers or one or more of its affiliates (including research analysts) may have a financial interest in securities of the issuer(s) or related investments, including long or short positions in securities, warrants, futures, options, derivatives, or other financial instruments. Al Rajhi Capital or its affiliates may from time to time perform investment banking or other services for, solicit investment banking or other business from, any company mentioned in this research document. Al Rajhi Capital, together with its affiliates and employees, shall not be liable for any direct, indirect or consequential loss or damages that may arise, directly or indirectly, from any use of the information contained in this research document.

This research document and any recommendations contained are subject to change without prior notice. Al Rajhi Capital assumes no responsibility to update the information in this research document. Neither the whole nor any part of this research document may be altered, duplicated, transmitted or distributed in any form or by any means. This research document is not directed to, or intended for distribution to or use by, any person or entity who is a citizen or resident of or located in any locality, state, country or other jurisdiction where such distribution, publication, availability or use would be contrary to law or which would subject Al Rajhi Capital or any of its affiliates to any registration or licensing requirement within such jurisdiction.



Disclaimer and additional disclosures for Equity Research

Disclaimer

This research document has been prepared by Al Rajhi Capital Company ("Al Rajhi Capital") of Riyadh, Saudi Arabia. It has been prepared for the general use of Al Rajhi Capital's clients and may not be redistributed, retransmitted or disclosed, in whole or in part, or in any form or manner, without the express written consent of Al Rajhi Capital. Receipt and review of this research document constitute your agreement not to redistribute, retransmit, or disclose to others the contents, opinions, conclusion, or information contained in this document prior to public disclosure of such information by Al Rajhi Capital. The information contained was obtained from various public sources believed to be reliable but we do not guarantee its accuracy. Al Rajhi Capital makes no representations or warranties (express or implied) regarding the data and information provided and Al Rajhi Capital does not represent that the information content of this document is complete, or free from any error, not misleading, or fit for any particular purpose. This research document provides general information only. Neither the information nor any opinion expressed constitutes an offer or an invitation to make an offer, to buy or sell any securities or other investment products related to such securities or investments. It is not intended to provide personal investment advice and it does not take into account the specific investment objectives, financial situation and the particular needs of any specific person who may receive this document.

Investors should seek financial, legal or tax advice regarding the appropriateness of investing in any securities, other investment or investment strategies discussed or recommended in this document and should understand that statements regarding future prospects may not be realized. Investors should note that income from such securities or other investments, if any, may fluctuate and that the price or value of such securities and investments may rise or fall. Fluctuations in exchange rates could have adverse effects on the value of or price of, or income derived from, certain investments. Accordingly, investors may receive back less than originally invested. Al Rajhi Capital or its officers or one or more of its affiliates (including research analysts) may have a financial interest in securities of the issuer(s) or related investments, including long or short positions in securities, warrants, futures, options, derivatives, or other financial instruments. Al Rajhi Capital or its affiliates may from time to time perform investment banking or other services for, solicit investment banking or other business from, any company mentioned in this research document. Al Rajhi Capital, together with its affiliates and employees, shall not be liable for any direct, indirect or consequential loss or damages that may arise, directly or indirectly, from any use of the information contained in this research document.

This research document and any recommendations contained are subject to change without prior notice. Al Rajhi Capital assumes no responsibility to update the information in this research document. Neither the whole nor any part of this research document may be altered, duplicated, transmitted or distributed in any form or by any means. This research document is not directed to, or intended for distribution to or use by, any person or entity who is a citizen or resident of or located in any locality, state, country or other jurisdiction where such distribution, publication, availability or use would be contrary to law or which would subject Al Rajhi Capital or any of its affiliates to any registration or licensing requirement within such jurisdiction.

Explanation of Al Rajhi Capital's rating system

Al Rajhi Capital uses a three-tier rating system based on absolute upside or downside potential for all stocks under its coverage except financial stocks and those few other companies not compliant with Islamic Shariah law:

"Overweight": Our target price is more than 10% above the current share price, and we expect the share price to reach the target on a 12 month time horizon.

"Neutral": We expect the share price to settle at a level between 10% below the current share price and 10% above the current share price on a 12 month time horizon.

"Underweight": Our target price is more than 10% below the current share price, and we expect the share price to reach the target on a 12 month time horizon.

"Target price": We estimate target value per share for every stock we cover. This is normally based on widely accepted methods appropriate to the stock or sector under consideration, e.g. DCF (discounted cash flow) or SoTP (sum of the parts) analysis.

Please note that the achievement of any price target may be impeded by general market and economic trends and other external factors, or if a company's profits or operating performance exceed or fall short of our expectations.

Contact us

Dr. Sultan Altowaim

Head of Research

Tel : +966 11 836 5468

Email: Altowaims@alrajhi-capital.com

Al Rajhi Capital

Research Department

Head Office, King Fahad Road

P.O. Box 5561, Riyadh 11432

Kingdom of Saudi Arabia

Email: research@alrajhi-capital.com

Al Rajhi Capital is licensed by the Saudi Arabian Capital Market Authority, License No. 07068/37